Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients
Stopped when a blind review highlighted that at least 43% of patients had a virological response
Conditions
- Hepatitis C Virus Recurrence
Interventions
- DRUG: Silibinin (Legalon-SIL)
- DRUG: Saline
Sponsor
Rottapharm
Collaborators